Foropafant

Foropafant (SR27417) highly potent, competitive, selective and orally active antagonist of platelet-activating factor (PAF) receptor, with a Ki value of 57 pM for [3H]PAF binding, at least 5-fold lower than that of unlabeled PAF itself. Foropafant potently inhibits PAF-induced aggregation of rabbit and human platelets[1].

Product Specifications

CAS Number

[136468-36-5]

Product Name Alternative

SR27417

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Platelet-activating Factor Receptor (PAFR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/foropafant.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)C1=CC(C(C)C)=C(C2=CSC(=N2)N(CCN(C)C)CC2=CC=CN=C2)C(=C1)C(C)C

Molecular Formula

C28H40N4S

Molecular Weight

464.72

Precautions

H302, H315, H319, H335

References & Citations

[1]Herbert JM, et al. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J Pharmacol Exp Ther. 1991 Oct;259 (1) :44-51.